CollPlant Biotechnologies Financial Statements
NASDAQ: OPHIHealth CareIndustrial SpecialtiesUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
CollPlant Biotechnologies revenue and earnings
In fiscal 2025, CollPlant Biotechnologies generated $2.4 million in revenue, up 360.4% from fiscal 2024. CollPlant Biotechnologies reported a net loss of $11.5 million, compared with a loss of $16.6 million a year earlier. Gross margin was 64.8% (up from -215.5%) and operating margin -484.3%.
Diluted earnings per share came in at -$0.94. Over the last 5 fiscal years, OPHI's revenue has grown at a -17.3% compound annual rate (a contraction).
Summary generated from market data by MetaCap's automated system. Methodology
CollPlant Biotechnologies income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.37M | 515.00K | 10.96M | 299.00K | 15.64M | 6.14M | 2.32M | 5.01M | 463.00K |
| Revenue growth (YoY) | +360.39% | -95.30% | +3565.22% | -98.09% | +154.86% | +164.75% | -53.77% | +982.94% | — |
| Cost of Revenue | 835.00K | 1.63M | 1.99M | 400.00K | 2.00M | 3.00M | 1.88M | 1.66M | 48.00K |
| Gross Profit | 1.54M | -1.11M | 8.97M | -101.00K | 13.64M | 3.13M | 439.00K | 3.35M | 415.00K |
| Operating Expenses | 13.02M | 16.14M | 16.48M | 17.00M | 13.57M | 34.00K | 3.30M | 2.18M | 6.37M |
| Research & Development | 8.19M | 10.52M | 10.48M | 10.26M | 7.63M | 4.07M | 4.41M | 3.88M | 584.00K |
| Selling, General & Admin | — | — | — | — | — | — | 3.66M | 3.72M | 2.47M |
| Operating Income | -11.48M | -17.25M | -7.51M | -17.10M | 65.00K | -5.60M | -7.63M | -4.25M | -5.96M |
| Interest Expense | — | — | — | — | — | — | 3.30M | 2.18M | 47.00K |
| Other Income (Expense) | -6.00K | 642.00K | 493.00K | 172.00K | 172.00K | -175.00K | -3.53M | — | — |
| Income Tax | — | 45.99M | 59.99M | — | — | — | — | — | — |
| Net Income | -11.49M | -16.61M | -7.02M | -16.93M | 237.00K | -5.77M | -11.16M | -6.25M | -6.05M |
| Net Income growth (YoY) | — | — | — | -7241.35% | — | — | — | — | — |
| EPS (Basic) | -0.94 | -1.45 | -0.62 | -1.53 | 0.02 | -0.84 | -2.23 | 1.43 | — |
| EPS (Diluted) | -0.94 | -1.45 | -0.62 | -1.53 | 0.02 | -0.84 | -2.23 | 1.43 | — |
| Shares Outstanding (Basic) | 12.20M | 11.45M | 11.39M | 11.03M | 9.97M | 6.89M | 4.99M | 4.38M | 2.66M |
| Shares Outstanding (Diluted) | 12.20M | 11.45M | 11.39M | 11.03M | 11.97M | 6.89M | 4.99M | 4.38M | — |
| EBITDA | -10.57M | -16.21M | -6.41M | -16.02M | 838.00K | -4.94M | -7.09M | -3.90M | -5.73M |
| Gross Margin | 64.78% | -215.53% | 81.83% | -33.78% | 87.18% | 51.08% | 18.94% | 66.91% | 89.63% |
| Operating Margin | -484.31% | -3349.71% | -68.55% | -5718.06% | 42.00% | -91.23% | -329.21% | -84.66% | -1286.61% |
| Net Margin | -484.56% | -3225.05% | -64.05% | -5660.54% | 1.52% | -94.09% | -481.62% | -124.63% | -1306.91% |
This table shows 9 annual periods of CollPlant Biotechnologies's income statement, from FY 2025 back to FY 2017, across 19 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow OPHI's reporting calendar. What is a income statement?